Summary:
A Phase 2a, Multicenter, Randomized, Double-Blind,
Placebo-Controlled, 3-Arm Study to Assess the Safety, Tolerability,
PK Profile, and Symptom Response of a 7-Day Dosing with
REL-1017 25 mg QD and 50 mg QD as Adjunctive Therapy in the
Treatment of Patients Diagnosed with Major Depressive Disorder
Qualified Participants Must:
• Males and Females between 18 and 65 years of age
•
Diagnosed with recurrent MDD
Qualified Participants May Receive:
Compensation for time and travel